26 November 2025 in IEEE Transactions on Instrumentation and Measurement
The power generation and loads of photovoltaic (PV) systems are inherently intermittent, periodic, and stochastic, resulting in non-stationary dynamic fluctuations in line currents. These dynamics have overlapping spectral features with DC series arcs, which increases the likelihood of false alarms and reduces the accuracy of arc detection. To address this problem, a DC series arc diagnosis method based on asymmetrical Gini impurity is proposed to reduce false alarm rate while ensuring accuracy. First, arc fault current data under various operating conditions are collected through experiments. To mitigate the impact of periodic fluctuations and enhance the detection of transient current changes, a multi-step differential processing method is employed. Second, the time-domain and frequency-domain features of arc faults are extracted from the differential signal to construct a high-dimensional feature vector. To reduce redundant features, the clustering algorithm is applied to identify and group features demonstrating analogous classification performance, and the asymmetric Gini impurity (AGI) is introduced to analyze feature significance. Finally, a random forest model based on AGI is utilized for DC series arc diagnosis. The experimental results demonstrate that the proposed method not only achieves high diagnosis accuracy and effectively reduces the false alarm rate, but also completes fault detection within 60 ms.
24 November 2025 in IEEE Transactions on Computational Biology and Bioinformatics
Computational drug repositioning technology can identify potential uses for existing drugs and reduce the time and cost required in the drug development process. How to find appropriate representations of drugs and diseases to predict the associations between the two is the main objective of such tasks. With the emergence of graph neural networks in recent years, researchers learned drugs and diseases via graphs in a bid to improve the prediction accuracy. However, there are three key problems that have not been adequately studied: 1) They usually place drug disease association graphs, drug-drug similarity graphs, and disease-disease similarity graphs under the same se mantic space for learning, which lose the higher-order features of the different graphs. 2) They assign equal weight to each neighbor node when aggregating based on the drug disease association graph, but the effect and mechanism of a drug in treating different diseases are not consistent. 3) They adopt residual connections to enhance the role of the root node without considering that this operation amplifies the effect of anomalous features. In view of this, we first propose a graph attention network-based spatial decomposition method for drug repositioning. Specifically, we reduce the dimensions of the feature space by spatial decomposition and initialize the drug and diseaseem bedding in the drug-similarity subspace, disease-similarity subspace, anddrug-disease association subspace, respectively. The representations of drugs and diseases are jointly captured in the corresponding subspace based on similarity and therapeutic associations. Moreover, the extent of the associations is measured through the graph attention mechanism to explore higher-order neighborhood relationships between drugs and diseases. Finally, we introduce a targeted residual connection for personalized propagation of node features. Experiments on four benchmark datasets show that our proposed architecture outperforms current state-of-the-art approaches. The code of this paper can be accessed at https://github.com/shaoqiezi/GATSD.
1 January 2026 in IEEE Transactions on Instrumentation and Measurement
10 June 2026 in IEEE Journal of Biomedical and Health Informatics
Predicting drug-target binding affinity is a crucial step in drug discovery, with the aim of estimating the strength of interactions between unknown drug-target pairs. In recent years, with the advancement of graph neural networks and self-supervised learning, numerous novel approaches have been proposed by researchers. However, these methods still exhibit the following drawbacks: 1) They only consider drug-target interaction information when learning relationship features, resulting in low information density and an inability to obtain high-quality representations. 2) The integration of cross-scale features is rigid, with features across different scales showing no correlation, failing to reflect the consistency of the same entity's features across different perspectives. 3) They employ outdated Graph Contrastive Learning (GCL) strategies, which have been proven to yield highly biased estimates. Therefore, to address these challenges, we propose a method that Enhances cross-scale feature Mutual information via Heterogeneous Graph Contrastive Learning for predicting Drug-Target binding Affinity (EMHGCL-DTA). The proposed model reconstructs the relationship network on the macro scale, incorporating similarity information while preserving drug-target interaction data. Furthermore, to establish a connection between macro-scale and micro-scale features, our similarity information is derived directly from the molecular structures of drugs and targets. In addition, we introduce a pertinent unbiased feature augmentation strategy to enhance the representations of drugs and targets. The novelty and effectiveness of the EMHGCL-DTA model are validated on two datasets, where it outperforms state-of-the-art methods.